Related Experiment Videos

Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo

G J Dougherty1, J D Thacker, R S Lavey

  • 1Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, Canada.

Insights

Interleukin-6 (IL-6) gene transfer reduced tumor growth in mice, but its effectiveness depended on the tumor site. Systemic IL-6 showed antitumor activity, particularly in lung tumors, and influenced macrophages.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Interleukin-6 (IL-6) is a multifunctional cytokine with potential roles in cancer.
  • Understanding IL-6's direct antitumor activity is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the antitumor potential of interleukin-6 (IL-6).
  • To determine the impact of IL-6 expression and administration on tumor growth in vivo.
  • To explore the role of IL-6 in the tumor microenvironment.

Main Methods:

  • Retrovirus-mediated gene transfer to express human IL-6 in murine fibrosarcoma cells (Fsa-R).
  • In vivo tumor implantation (intravenous, subcutaneous) in syngeneic mice.
  • Intraperitoneal and intratumoral administration of IL-6.

Main Results:

  • Engineered Fsa-R cells expressing IL-6 showed significantly reduced tumorigenicity in vivo.
  • Intraperitoneal IL-6 administration inhibited lung tumor growth but not subcutaneous tumors.
  • Local IL-6 expression or intratumoral administration was required to inhibit subcutaneous tumor growth.
  • Subcutaneous tumors from IL-6-producing cells contained increased macrophages.

Conclusions:

  • Systemic IL-6 exhibits site-dependent antitumor activity, with greater efficacy against lung metastases.
  • Local IL-6 delivery or expression is necessary for inhibiting subcutaneous tumor growth.
  • IL-6 plays a significant role in the recruitment, proliferation, and/or survival of tumor-associated macrophages.

Related Concept Videos